Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$23.4B
251M shares
52-week range
$79.52 – $124.00
31% from low
Exchange
NASDAQ
ADRC
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
www.biontech.deNo one on the platform currently holds BNTX.
| Institution | Shares | Reported |
|---|---|---|
| Bridgewater Associatesas of 2025-12-31 | 4,927 | $469.1K |
No one on the platform has traded BNTX yet.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.9B | -30.0% | $-5.56 | $-5.85–$-5.26 | — | 7 |
| 2027 | $1.9B | +0.2% | $-5.73 | $-7.50–$-3.95 | — | 8 |
| 2028 | $2.4B | +27.7% | $-4.35 | $-11.13–$1.21 | — | 13 |
| 2029 | $2.2B | -9.0% | $-4.56 | $-5.74–$-3.12 | — | 10 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 6 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-04 | $-2.40 | $-3.70 | -54.3% |
| 2026-05-05 | $-2.54 | $-2.43 | +4.4% |
| 2026-03-10 | $-0.22 | $-0.38 | -72.7% |
| 2025-11-03 | $-1.12 | $-0.14 | +87.5% |
| 2025-08-04 | $-2.69 | $-1.82 | +32.3% |
| 2025-05-05 | $-2.48 | $-1.82 | +26.5% |
| 2025-03-10 | $0.46 | $1.15 | +148.7% |
| 2024-11-04 | $-1.74 |
| $0.89 |
| +151.1% |
| $24.4B |
| — |
| NTRANatera, Inc. | $309.93 | -0.27% | $44.4B | — |
| PHGKoninklijke Philips N.V. | $27.29 | -0.33% | $26.7B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$ABCL short interest might be due to very different reasons, e.g. hedging against long positions. therefore it can take a while until those are significantly reduced. when $BNTX launched their vaccine, it took more than half a year until the price finally quadrupled for a very short time.
View on StockTwits ↗$BNTX Nice. The new CEO is an expert at transitioning clinical trial results into approved and marketed drugs. Seems like the company is confident enough to prepare for the new phases. The remainder of this year will be amazing with great trial data. JMO
View on StockTwits ↗BioNTech Just Named a New CEO. Here's What Guido Oelkers' Appointment Means for the Stock: https://www.fool.com/investing/2026/08/13/biontech-just-named-a-new-ceo-heres-what-guido/ $BNTX
View on StockTwits ↗$MRNA $PFE $BNTX $GSK Bygone 2021 vaccine mandates vs. shorts who thought removing the mandates would eliminate demand and bankrupt vaccine companies:
View on StockTwits ↗$MRNA $PFE $BNTX $GSK Reading the antivaccine comments here is like reading Yelp reviews of steakhouses written by vegetarians. They’re interesting, sometimes funny, but ultimately useless because they don’t even know what meat tastes like.
View on StockTwits ↗$BNTX $MRNA $PFE The Science is laughing at the antivaccine clowns.
View on StockTwits ↗$BNTX $MRNA $PFE These two should be sharing a prison cell with their buddies Fauci & Gates
View on StockTwits ↗$TPST Will there be another day with gains of 4,000% or more here? $BNTX $IBIO $IBM
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.